Indications for: MYRBETRIQ
Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency, as monotherapy or in combination with solifenacin. Neurogenic detrusor overactivity (NDO) in pediatric patients aged ≥3yrs and weighing ≥35kg.
Swallow tabs whole with water. Initially 25mg once daily; may increase to max 50mg once daily after 4–8 weeks if needed. Severe renal impairment or moderate hepatic impairment: max 25mg once daily. ESRD, requiring dialysis, or severe hepatic impairment: not recommended.
<3yrs: not established. Swallow tabs whole with water. Take with food. ≥3yrs (≥35kg): Initially 25mg once daily; may increase to max 50mg once daily after 4–8 weeks if needed. Severe renal impairment or moderate hepatic impairment: max 25mg once daily. ESRD, requiring dialysis, or severe hepatic impairment: not recommended.
Do not substitute tabs and granules on a mg-per-mg basis. Severe uncontrolled hypertension: not recommended. Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the tongue, hypopharynx, or larynx occurs. Pregnancy. Nursing mothers.
Beta-3 adrenergic agonist.
May potentiate CYP2D6 substrates (eg, metoprolol, desipramine); adjust dose and monitor esp. with narrow therapeutic index drugs (eg, thioridazine, flecainide, propafenone). Concomitant digoxin: use lowest digoxin dose initially (monitor and titrate).
Adults: hypertension, nasopharyngitis, UTI, headache; also with solifenacin: dry mouth, constipation, tachycardia. Children: UTI, nasopharyngitis, constipation, headache.
Generic Drug Availability:
Tabs—30, 90; Granules—1